Background: Two independent studies reported that 16% of people who self-monitor blood glucose used incorrectly coded meters. The degree of analytical error, however, was not characterized. Our study objectives were to demonstrate that miscoding can cause analytical errors and to characterize the potential amount of bias that can occur. The impact of calibration error with three selfblood glucose monitoring systems (BGMSs), one of which has an autocoding feature, is reported.
INTRODUCTION E
VIDENCE FROM THE Diabetes Control and Complications Trial 1 and the United Kingdom Prospective Diabetes Study 2 showed that maintaining blood glucose at normal or nearnormal levels was important in delaying the onset or preventing the development of diabetes mellitus complications. Better blood glucose control resulted in lower A1c levels, and lower A1c contributed to better clinical outcomes for subjects with diabetes. 3 While maintaining normoglycemia is the target, it is regarded as an elusive goal by many diabetologists. As quoted in a recent editorial, "clinicians often sit in their offices or surgeries and wonder why the home blood-glucose monitoring record prepared by the patient is at odds with the objective measure of control given by hemoglobin A1c." 4 There can be many reasons for this dilemma, some of which may involve the glucose measurement, the quality of the measurement, or the role that glucose testing plays in the individual's disease management. There have been debates on the analytical quality of the glucose result required to provide optimal glycemic control, as well as guidelines on the quality of the analytical devices. There are a number of published quality specifications for self-monitoring of blood glucose. [5] [6] [7] Early recommendations suggested an imprecision of less than 10%. While the American Diabetes Association consensus group originally recommended that all self-blood glucose monitoring systems (BGMSs) should have a total error of Ͻ10%, this was subsequently revised to Ͻ5%. 6 The International Organization for Standardization 7 suggested that 95% of the measurements should be within Ϯ20% for glucose concentrations Ն75 mg/dL (4.2 mmol/L) and within Ϯ15 mg/dL (0.83 mmol/L) for levels Ͻ75 mg/dL (4.2 mmol/L).
Skeie et al. 8 investigated the analytical performance of five self-BGMSs in the hands of one experienced laboratory technician and 422 patients. The rationale for the study arose from the authors' observation that most evaluations of technical performance of BGMSs had been undertaken by healthcare professionals rather than by patients. Yet, it is well known that user error accounts for much of the total error in patient self-monitoring. Skeie et al. 8 found that patient blood glucose measurements demonstrated a greater deviation from the laboratory results, the reference point in this study, than the results produced by the laboratory technician using the same BGMS.
Skeie et al., 9 in another study, sought to define quality specifications for self-BGMSs from an analysis of patient responses to a detailed questionnaire. The combination of an imprecision of Յ5% [expressed as a coefficient of variation (CV)] and a bias of Յ5% was considered to meet the expectations of Ͼ75% of the respondents for clinical situations other than hypoglycemia.
There may be many reasons for the observation that patient performance was inferior to that of a laboratory professional, some of which may relate to the lack of technical expertise. This has been addressed in recent years through design engineering and increasing analytical system robustness.
Variation in analytical performance resulting from incorrect meter calibration by selection of the wrong "calibration algorithm," the socalled "calibration coding error," has been objectively documented. Both Raine 10 and Kristensen et al., 11 after checking the calibration code of the BGMS being used by the patients, found that the incidence of miscoding was 16% in individuals with diabetes participating in their studies.
The impact of calibration error with three self-BGMSs is reported here, in one of which the potential for a calibration error has been obviated by the design of the system. The study was conducted with a cohort of subjects with diabetes at a diabetes center.
SUBJECTS AND METHODS

Subjects
The study was undertaken with the cooperation of 50 subjects with diabetes (18 men, 32 women) attending a diabetes center in a large hospital complex. Informed consent was obtained from all subjects, and the protocol was approved by the site institutional review board. The age range of the subjects was 23-82 years, with a median age of 59 years. An effort was made to obtain a range of blood glucose results by inviting the subjects to attend at different times during the day. The blood glucose concentrations varied between 48 and 259 mg/dL (2.7 and 14.4 mmol/L), with a median of 122.8 mg/dL (6.8 mmol/L). The subject hematocrit levels ranged from 34% to 51%, with a median of 41.5%.
Analytical systems
The study was performed with three selfBGMSs: System A was the Ascensia ® CON-TOUR ® (Bayer HealthCare, LLC, Tarrytown, NY), System B was the One Touch ® Ultra ® (LifeScan, Milpitas, CA), and System C was the FreeStyle™ (formerly TheraSense™, now Abbott Diabetes Care, Alameda, CA). All three BGMSs use an electrochemical technology. Each system consisted of a meter and dry reagent test strips. System A can be used for venous, arterial, or capillary blood glucose testing, while the other two systems provide for capillary blood glucose testing only. Four meters of each system were used in the study. All were referenced to give plasma glucose values. For Systems B and C, a single reagent lot was used. Two meters of each BGMS were coded with the correct code. One meter of each make was calibrated using a code number above and below the correct value (codes 1 and 49 for System B, and codes 7 and 41 for System C). These code numbers were determined prior to the start of the study. The evaluation test strip lots were arbitrarily ordered from a commercial supplier. For System A, a common reagent lot was used with two meters. To challenge the calibration process, a different reagent lot was used with each of the remaining two meters. An identification number was assigned to each of the 12 meters. The meters were randomized to determine the order of testing, and a different testing order was generated for each of the 50 participants. All analyses were performed by a certified diabetes educator, who was trained in the use of the BGMS and in the detail of the study protocol. The comparative laboratory glucose method was a Yellow Springs Instrument (YSI) (Yellow Springs, OH) blood glucose analyzer (Model 2300 Stat Plus).
Experimental protocol
Four finger punctures were performed by the certified diabetes educator on each subject. Four blood glucose measurements were made from each of the first three punctures. Samples for the laboratory glucose assay and a hematocrit determination were obtained from the fourth fingerstick. With each puncture, the initial blood drop was wiped away, and a fresh blood drop was expressed for a blood glucose assay. The used drop was wiped away, and a fresh one expressed for each subsequent assay. An additional 250-600 L of blood was collected in a Microtainer ® Brand Tube (Becton Dickinson and Co., Franklin Lakes, NJ) with a plasma separator and lithium heparin as an anticoagulant, for the comparative plasma glucose determinations. The samples were centrifuged within 20 min of collection using a StatSpin ® (Norwood, MA) centrifuge. The plasma was frozen and sent to a laboratory for glucose determinations on the YSI analyzer. A capillary tube hematocrit determination was performed on-site by the certified diabetes educator.
Accuracy and precision of the glucose methods
Assays of six glucose control sera, with target values established at Bayer Diabetes Care using a plasma glucose method traceable to the National Institute of Standards and Testing and Centers for Disease Control and Prevention reference method, 12 were used to confirm the accuracy (traceability) and precision of the YSI analyzer. The controls were assayed in duplicate for five runs over at least 3 days before the start of the study and one time each week that the evaluation was in progress. When determining differences between the comparative method and the control target values, absolute differences were used for the two levels with glucose concentrations Ͻ75 mg/dL (Ͻ4.2 mmol/L), and percent differences were used for the four controls containing glucose Ն75 mg/dL (Ն4.2 mmol/L). Paired results from the two correctly coded meters of each system were used to assess the precision of the three BGMSs.
Statistical analysis
Laboratory glucose analyzer precision was calculated using the formulae from NCCLS EP5-A, Appendix C. 13 Outlier tests using the within-method and between-method protocols described in NCCLS EP9-A 14 were applied. The within-method analysis was performed on the Replicate 1 and 2 pairs (correctly coded) of each BGMS. The between-method test was performed on the results obtained with each meter and the results mean obtained with the YSI analyzer. If a result was identified as an outlier with any of the three BGMSs, the data from that subject were removed from the analyses. Results from two subjects were removed because of within-method (n ϭ 1) and between-method (n ϭ 1) outliers. Relationships between results obtained with the three BGMS and the YSI analyzer were determined using the linear method comparison provided in the Analyseit™ (version 1.71, Analyse-it Software, Ltd., Leeds, UK) add-in software to Microsoft ® (Redmond, WA) Excel. The linear relationships of the results were determined using the Pearson correlation function of the same software.
Error grid analysis
Error grid analysis 15 was employed to evaluate the clinical accuracy of the BGMS in comparison with the results of a metrologically traceable laboratory plasma glucose method.
RESULTS
Accuracy and precision of the laboratory glucose method
The control sera target values, grand means of YSI analyzer results, and overall SDs and CVs for each control are given in Table 1 . No corrections were made to the data to compensate for biases.
BGMS reproducibility
The reproducibility of the three systems was assessed using replicate blood glucose assays obtained with meters set to the correct code number (Systems B and C) or the same test strip lot (System A). The average CV, calculated from the assays of the 50 capillary blood samples, was determined for each system using the variances of the replicates. The results (Table 2) show that the precision of the three BGMSs was comparable, with average CVs ranging from 4.0% to 4.8%. The mean BGMS values were also statistically and analytically equivalent.
Agreement of miscoded meter data with results from correctly coded systems (within-system, meter-to-meter comparisons)
The differences of results obtained with miscoded meters from results obtained with the first replicate of correctly coded meters were determined for each System (Coding Variable Result minus Correctly Coded Result). Different test strip lots were used as coding challenges for System A, since the automatic coding system could not be changed. The differences are plotted in Figure 1 . Results obtained with the second replicate of the correctly coded system were plotted to show within-system variability. Absolute differences (mg/dL or mmol/L) were BAUM ET AL. 350 Numbers of greater significance were used with mmol/L units to reconcile the CVs with the mg/dL units. calculated for samples with glucose concentrations Ͻ75 mg/dL (4.2 mmol/L), and relative percent differences were calculated for those samples having glucose levels Ն75 mg/dL (Ն4.2 mmol/L). Three samples had glucose concentrations Ͻ75 mg/dL (Ͻ4.2 mmol/L), and 47 had glucose levels Ն75 mg/dL (Ն4.2 mmol/L). The medians of the differences of the glucose results obtained using miscoded meters and the second replicate of the correctly coded meters are presented in Table 3 .
Target value Grand mean SD
Analytical and clinical accuracy of correctly coded and miscoded systems
Regression statistics comparing results obtained with correctly coded and miscoded meters to the laboratory glucose method are given in Table 4 . The mean glucose values obtained using each meter and the YSI analyzer, and the medians of the biases, are also presented. By YSI analysis, only one sample was determined to have a glucose concentration Ͻ75 mg/dL (Ͻ4.2 mmol/L). Glucose results obtained with each correctly coded and miscoded system were plotted against the mean YSI analyzer values in Figure 2 . Error grid analysis was applied to the data to show the clinical relevance of deviations from the comparative plasma glucose results. The percentages of results that fell into each error grid zone for the correctly coded and miscoded systems are shown in Table 5 .
System A performance was not significantly affected when different test strip lots were used to challenge the autocoding feature. The regression analyses (Table 4) showed no statistically significant proportional [95% confidence intervals (CIs) of the slopes included 1.0] or constant (95% CI of the y-intercepts included 0.0) biases. The medians of the percent biases were Ϫ2.1% for both replicates of the designated control lot and ϩ0.4 and Ϫ1.1% for the lots used to challenge the autocoding feature. Error grid analysis showed that all System A glucose results with Lot B fell within Zone A. Only one of 50 results obtained with each of the challenge lots (Lots A and C) was in Zone B ( Fig. 2A) .
The performance of the two correctly coded System B meters was statistically equivalent to that of the YSI plasma glucose method. The medians of the percent biases were Ϫ1.6 and Ϫ2.8%. The meter miscoded to Code 1 gave results that had a small constant bias, with the 95% CI of the y-intercept being 0.97 to 15.25 mg/dL (0.05 to 0.85 mmol/L). However, the BAUM ET AL. 352 In the case of System C, no proportional or constant biases were observed with the two correctly coded meters, with median biases of Ϫ0.3% and Ϫ1.0%. When the meters were set to incorrect codes, the 95% CI of the slopes and y-intercepts did not include 1.0 or 0.0, respectively (Table 4) , with statistically significant proportional and constant biases. The miscodings resulted in bias medians of ϩ43.5% and Ϫ16.2%, respectively. All results obtained with the correctly coded meters were inside Zone A of the error grid. Clinical accuracy was compromised when the meter was set to Code 7. Only 2% of the results (n ϭ 1) were in Zone A, 94% were in Zone B, and 4% (n ϭ 2) were in Zone C. One of the results falling in Zone C [82 mg/dL (4.5 mmol/L) by the YSI analyzer] represented a 71% overestimation of the blood glucose concentration. The other result exceeded the YSI analyzer result of 48 mg/dL (2.7 mmol/L) by 34 mg/dL (1.9 mmol/L), creating the potential for missing a developing hypoglycemic event. The System C meter set to Code 41 showed a marked effect on clinical accuracy, with 66% of the results in Zone A and 34% in Zone B.
DISCUSSION
The comparative precision of the three correctly coded BGMSs was excellent. Using the variance between replicates, the average CVs were 4.1%, 4.0%, and 4.8% for Systems A, B, and C, respectively. The three systems showed no statistically significant differences from the YSI analyzer results. The medians of the percent differences were between Ϫ0.3% and Ϫ2.8% for the three systems (six meters), indicating good accuracy.
Miscoding of Systems B and C, using certain incorrect calibration codes, resulted in statistically and clinically significant BGMS result inaccuracies. In one instance with each system, the medians of the differences between results obtained with miscoded and correctly coded meters or with miscoded meters and the YSI analyzer were greater than Ϯ30%. With both systems, the number of results falling into error grid zones indicating altered clinical action was Ͼ90%. Similar testing with System A, the autocoding BGMS, did not show such inaccuracies when challenged with three test strip lots.
Skeie et al. 8 reported the performance of five BGMSs obtained by 442 patients and a laboratory-trained technician. The imprecision of the five systems studied was 7%, 11%, 18%, 18%, and 20% in the hands of patients and was between 2.5% and 5.9% in the hands of the technician. For three of the systems, the patients' results showed a larger deviation from the laboratory results than was observed with the technician's results. The technician's performance with any one of the systems did not predict patient performance with that system. In this study, 8 no BGMS used by patients (but two operated by the technician) met published BAUM ET AL. 354 quality specifications. The analytical quality of patients' results was not related to whether they had chosen a system based on recommendation from a healthcare professional, were only educated in self-monitoring of blood glucose, or performed a blood glucose test less then seven times a week. Skeie et al. 8 noted that the patients used several lots of test strips while the technician used only one, and this may have contributed to the better performance of the systems when used by the technician. The authors also concluded that "user errors and lack of instrument robustness, both of which are dependent on the specific system" are likely to have accounted for the differences between the patients' and the technician's results. The observations made by Skeie et al. 8 are borne out in the study reported in the present paper, indicating that coding errors are a potential source of inaccuracy in self-monitoring of blood glucose.
Studies by Raine 10 and Kristensen et al. 11 showed that non-matching calibration codes (coding errors) were found in 16% of the patient BGMSs that were audited. In the former study, 335 subjects were asked to bring information on strip and meter calibration codes. Information was not provided by 134 patients, so the analysis was undertaken on 201 patient records. A number of BGMSs were used. All patients indicated that they had received instruction in the use of their personal BGMS. Patients with non-matching codes had a higher mean A1c value compared with those with correct codes (8.2% vs. 7.7%), although the difference was not significant (P ϭ 0.4688). Erroneous codes were found for 12% of the type 1 and 17% of the type 2 diabetes populations.
The study by Kristensen et al. 11 was conducted to determine the effect of user training on performance before operating an unfamiliar BGMS. One hundred subjects were divided into two groups. One group received instruction on the use of the BGMS by a medical laboratory technician. The other group received the BGMS by mail and had to rely on the accompanying instructions to learn the operation of the BGMS. Both groups tested at home and met with the medical laboratory technician for consultation after 4 weeks. At the time of final study consultation, 16% of the study subjects had miscoded the BGMS, and 17% reported difficulty in coding the BGMS.
Skeie et al. 8 have also pointed out that there is a large literature on the importance of patient education in achieving good quality blood glucose measurement. [16] [17] [18] They concluded that all new BGMSs should be tested by patients before a product launch to develop a pragmatic quality specification for each system. Skeie et al., 9 in another study that was based on questioning individuals with type 1 diabetes as to their quality requirements, indicated that a system with an imprecision of Ͻ5% and a bias of Ͻ5% met 75% of the patients' needs in clinical situations other than hypoglycemia.
Evaluation of performance by patients enables the manufacturer, educator, and patient to understand the procedural strengths and weaknesses of a BGMS, along with the operation routine, and allows them to devise a training scheme that supports good analytical performance. Many manufacturers perform this type of study to develop training recommendations and literature.
The UK Medicines and Healthcare Regulatory Agency has evaluated a number of selfBGMSs in recent years, testing the "operator dependency" as part of the evaluation protocol. In one UK Medicines and Healthcare Regulatory Agency study, the TheraSense FreeStyle system 19 gave errors of up to 79 mg/dL (4.4 mmol/L) at 159 mg/dL (8.8 mmol/L) glucose when an incorrect calibration coding was used (found testing 10 different calibration codes). The GlucoMen (A. Menarini Diagnostics, Florence, Italy) Glycó 20 showed variations up to 27 mg/dL (1.5 mmol/L) (using 10 different calibration codes), while the MediSense ® (Abbott Diabetes Care, Alameda, CA) Optium™ system 21 gave variations of up to 18 mg/dL (1.0 mmol/L) at 153 mg/dL (8.5 mmol/L) glucose (using eight different calibration codes). The One Touch Ultra 22 was shown to give variations up to 36 mg/dL (2.0 mmol/L) when 13 different calibration codes were used. The Accu-Chek ® systems 23, 24 (Roche Diagnostics, Indianapolis, IN) did not appear to show any significant variation if coding errors were made (nine and eight studied, respectively), although these reports indicated that the possibility of using strips from differ-ent variants of the Accu-Chek ranges might give errors.
Reference has already been made to recommendations on self-BGMS analytical performance. Boyd and Bruns, 25 using modeling of errors in insulin dosage, noted that errors in insulin dosage would be less likely to occur if the total error for glucose measurement was Ͻ5-6%. This analysis begins to relate the potential for error in the wider context of clinical outcomes, an area of validation that is very difficult to undertake in experimental conditions and to identify in routine clinical practice. There are few publications on audits of analytical error, although some attempts have been made to perform this in the laboratory setting. At the other extreme, an analysis of healthcare negligence litigation will identify a number of examples, some specifically in relation to glucose testing. Errors in relation to the misuse of glucose meters have been reported in the past, but as the number of procedural steps has been reduced (e.g., the need to wipe the strip or time reactions), the incidence of errors has diminished. This has led to an improvement in training compliance, as a result of reduced complexity of operation.
CONCLUSIONS
While modern BGMSs are beginning to approach the clinical performance criteria recommended, when used in experienced hands, it is clear from this study that the potential still exists with some systems for large discrepancies in results (Ϯ30% or more), particularly when meters are inadvertently miscoded by the layuser of the BGMS. This, together with the reported high frequency of patients using incorrectly coded meters 10, 11 and the differences shown between patient and healthcare professional performances, 8, 9 confirms the importance of using a BGMS that has automatic coding capability. BGMS results reported here confirm that the accuracy of a BGMS can be significantly negatively affected by coding errors. The data collected in this study characterize the maximum potential analytical errors due to coding errors and may not reflect the typical error obtained with miscoding.
Coding errors are only one of a number of user and BGMS error sources (e.g., user noncompliance, poor user testing technique, user failure to calibrate correctly, sample type variation, interferring substances, hematocrit variation, etc.). In future BGMS versions, it is incumbent upon manufacturers to ensure that BGMSs be developed to minimize or prevent the potential for both user error and system error. Accuracy of a BGMS is ultimately delivered by using an accurate reagent system, mitigating or preventing known sources of error, and improving system performance by providing intuitive ease-of-use.
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